PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This clinical study is aiming to determine the safest doses and schedule for the combination
of two drugs named palbociclib and avelumab.
The study will also be investigating how effective the combination is for a subgroup of
breast cancer patients whose cancer expresses the androgen receptor (AR) but not the
oestrogen (hormone) or HER2 receptors. Palbociclib is a drug used in routine care for
hormone-receptor (HR) positive and HER2 negative advanced breast cancer, the most common
subtype of breast cancer.
It is possible that the combination of palbociclib and avelumab will be a more effective
cancer treatment than each drug separately, but this is unknown and this study is needed to
establish the best dosage and schedule of each drug as well as how effective the combination
is.